Long-term effect of aripiprazole lauroxil on health-related quality of life in patients with schizophrenia

BACKGROUND: This post hoc analysis of clinical trial data evaluated long-term, self-reported mental and physical health-related quality of life (HRQoL) scores in schizophrenia patients receiving aripiprazole lauroxil (AL), an atypical long-acting injectable (LAI) antipsychotic approved for the treat...

Descripción completa

Detalles Bibliográficos
Autores principales: McEvoy, Joseph P., Weiden, Peter J., Lysaker, Paul H., Sun, Xiaowu, O’Sullivan, Amy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992347/
https://www.ncbi.nlm.nih.gov/pubmed/33761928
http://dx.doi.org/10.1186/s12888-021-03124-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992347/
https://www.ncbi.nlm.nih.gov/pubmed/33761928
http://dx.doi.org/10.1186/s12888-021-03124-2

Ejemplares similares